Why AstraZeneca Could Outperform

Here's how AstraZeneca's management is pushing forward and what they seem to like in their pipeline.

Jun 6, 2014 at 10:02AM

AstraZeneca (NYSE:AZN) develops, manufactures, and markets products for patients suffering from a wide spectrum of chronic and acute medical conditions, including cancer, autoimmune disorders, neuropathy, and cardiovascular disease.

AZN Chart

Fundamental outlook
The pharmaceuticals sub-industry tends to be relatively volatile, with significant downside susceptibility due to the top-line pressure from imminent patent expirations of many blockbuster drugs. In AstraZeneca's case, adjusted earnings declined 26% at constant currency, marking one of the worst performances the company has suffered in many years. Further, the company continues to reel from patent expirations and anticipates further declines in 2014 and 2015. This follows a $350 million loss to various products going generic -- including Seroquel IR, Atacand, Nexium and Merrem -- in 2013.

Unfortunately for AstraZeneca, it only gets worse as its blockbuster cholesterol drug, Crestor, faces an onslaught of generic competitors once it loses patent exclusivity in May 2016. Subsequently, most of Crestor's market share will likely go to competing statins, such as generic versions of Pfizer's (NYSE:PFE) Lipitor.

AstraZeneca stock currently has a dividend with a forward yield of 5.2%, and it approached 52-week highs last month amid buyout talks with Pfizer. More recently, however, the stock has faltered due to the Board's decision to reject Pfizer's latest proposal to acquire AstraZeneca for nearly $120 billion. Investors should be aware that the door is still open for an acquisition, even though it may be unlikely given how expensive the transaction would likely have to be. Under UK takeover laws, Pfizer cannot submit another bid for six months. But if AstraZeneca initiates buyout talks with Pfizer, a new bid can be submitted after three months.

This Fool's take
AstraZeneca's outlook may be much brighter than it seems. While fundamentally, there is the prospect of increasing revenue from emerging markets which should bolster future earnings, the key point for me is that Pfizer was wiling to pay a great deal for Astra, and Astra still rejected it. Obviously, AstraZeneca believes that it is worth more than this bid. As a conservative value investor, I like to put my money on the side of the big boys, and Pfizer happens to be the goliath on the pharmaceutical playground. I also like a tasty 5.2% dividend yield while I wait and watch. But what is Pfizer all excited about?

AstraZeneca has several blockbuster-worthy drug candidates that Pfizer wants -- in addition, of course, to the financial engineering aspect (Pfizer could lower its tax rate by domiciling in the UK). For starters, Pfizer has its eyes on AstraZeneca's PARP inhibitor, olaparib, for platinum-sensitive recurrent ovarian cancer, which has a scheduled PDUFA date in October. Used in combination with cediranib, olaparib has shown to be highly efficacious, well tolerated and versatile. The PFS differential is enormous, with the cediranib/olaparib combination yielding almost double the benefit (17.7 months) as compared to olaparib alone (9.0 months).

While ovarian cancer represents a considerable, multi-billion dollar market in the U.S., AstraZeneca's olaparib could be competitive in other notable markets, including prostate cancer, solid tumors and neoadjuvant breast cancer. These opportunities could be huge for AstraZeneca.

AstraZeneca also has several other intriguing oncology drugs, including AZD9291, a tyrosine kinase inhibitor, for non-small cell lung cancer.

Final thoughts
With a broad pipeline and lots of long-term opportunities, Astra's management is clearly confident that the company can return to revenue growth by 2017. I think this is a stock Fools should watch closely.

Speaking of dividends -- check out these top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.

Trevor Lowenthal has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers